Faculty

Elena Myasoedova, M.D., Ph.D.

Clinical Studies

Biorepository: RA patients in sustained remission (RAsM) Rochester, Minn.
The purpose of this study is to create a biorepository of biosamples from patients with rheumatoid arthritis (RA) in sustained remission. Identifying biomarkers associated with failure vs success of immunosuppressive treatments (DMARD) tapering is a critical need which will allow to maximize the benefits and safety of available treatments.
Spondyloarthritis Research Program: Biorepository of biosamples from patients with psoriatic arthritis Rochester, Minn.
The purpose of this study is to create a biorepository of biosamples from patients with psoriatic arthritis (PsA). This biorepository will enable future investigation of biomarkers associated with PsA.

Pharmacogenomics-driven Individualized Prediction of Treatment Response to Anti-rheumatic Medications in Patients with Rheumatoid Arthritis Rochester, Minn.
Study objective: Define pharmacogenomics markers and clinical phenotype features associated with response to RA treatments. Using electronical medical records data and a blood draw with DNA for genotyping from prospectively recruited patients seen in rheumatology clinic (n=100), we will identify genomic markers and leading phenotype features of responders to routinely used anti-rheumatic medications at 3 and 6 months of treatment based on disease activity score with 28-joint count (DAS28), accounting for socioeconomic factors, comorbidities, RA characteristics and prior anti-rheumatic medication use. We hypothesize that: Patients responding to antirheumatic medication(s) and their combinations share similar phenotype and/or genomic markers.